Currently, retrospective studies and case reports have demonstrated favorable efficacy and safety of neoadjuvant ALK-TKIs in resectable locally advanced NSCLC (Zhang et al., 2019; Hu et al., 2022; Sentana-Lledo et al., 2022). Here, ALK is linked to non-small cell lung carcinoma.